A股異動 | 麗尚國潮(600738.SH)大漲逾8% 參股醫美上游公司帕美朵
格隆匯5月31日丨麗尚國潮(600738.SH)大漲逾8%,報9.12元,高見9.28元創逾兩年新高,總市值71億元。改名後的麗尚國潮轉型換道,將目光首先落在了新消費領域,而新消費首選的賽道是女性的化粧品和醫美。5月28日晚間,麗尚國潮公吿稱,公司全資子公司麗尚控股擬向帕美朵(成都)生物科技有限公司增資3000萬元,增資完成後將持有其30%的股權。帕美朵主要產品涵蓋功效性醫學護膚品、皮膚科醫療器械、脱髮、家用美容儀(醫療器械)及耗材等領域,主要銷售渠道包括公立二三甲醫院等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.